Skip to main content

Covaxin found to neutralise ‘617 variant’ of COVID-19, says Anthony Fauci

Washington: Covaxin, India’s home-grown COVID-19 vaccine, has been found to neutralise the 617 variant of the deadly virus, White House chief medical adviser and America's top pandemic expert Dr Anthony Fauci said.

Fauci was speaking to reporters during a conference call on Tuesday. "This is something where we're still gaining data on a daily basis. But the most recent data, was looking at convalescent Sera of COVID-19 cases and people who received the vaccine used in India, the Covaxin. It was found to neutralise the 617 variants," he said.

"So, despite the real difficulty that we're seeing in India, vaccination could be a very, very important antidote against this," Fauci added.

The New York Times on Tuesday said Covaxin works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus. The antibodies attach to viral proteins, such as the so-called spike proteins that stud its surface.

Developed by Bharat Biotech in partnership with National Institute of Virology and the Indian Council of Medical Research, Covaxin was approved for emergency use on 3 January. Trial results later showed the vaccine has an efficacy of 78 percent.

Responding to a question, Dr Andy Slavitt, White House COVID-19 Response Senior Advisor, said that a strike team from the Center for Disease Control and Prevention is headed over to India to help coordinate this response.

"We are making sure that we are locating some of the raw materials necessary to create more vaccines in India, which I think is going to be an important help there," he said.

"We stand with the country of India during this very trying and tragic surge. We are working to deploy resources and supplies, including therapeutics, rapid testing kits, ventilators, PPE, and raw materials, that are needed to manufacture vaccines in India, and the CDC, which has a long history of working with and in India on public health measures, will be deploying a strike team to the country to support the public health efforts there," Slavitt said.

Given the strong portfolio of approved, highly effective and safe vaccines in the United States, the administration is looking at options to share AstraZeneca vaccines with other countries as they become available.

This should amount to around 60 million doses or so over the next two months, he added.

"The AstraZeneca vaccine is highly safe and effective, and approved in many parts of the world, and since it is not approved for use in the US, we do not need to use the AstraZeneca vaccine during the next few months," Slavitt said.

"We have sufficient supply of vaccines from Pfizer, Moderna, and Johnson & Johnson to accommodate our needs in the US," he added.



from Firstpost India Latest News https://ift.tt/3t7bGml

Comments

Popular posts from this blog

COVID-19 vaccination: Registration for citizens above 18 years of age starts today on CoWin, Aarogya Setu portals

The registration for COVID-19 vaccination for people above the age of 18 years in India started from today ( Wednesday, 28 April ). Those who are eligible for vaccination can register themselves on two applications, namely CoWin and Aarogya Setu, to book their slots for taking the vaccine jab. For those above the age of 18, coronavirus vaccination will start from 1 May. People above the age of 18 can take the following steps to register for the vaccination: Step 1 : Open the play store to download the CoWin app or visit CoWin.gov.in Step 2 : Register on the portal using your mobile number. You will receive an OTP. Enter it to complete the registration Step 3 : You will have to enter your personal details including the number of your photo identification Step 4 : After the registration, select the date, time, and venue for your COVID-19 vaccination Step 5 : Visit the vaccination centre with your appointment slip and receive your first jab Once a person receives the first jab, th...

7 leopard cubs die at Bengaluru biological park after virus attack: Report

Seven leopard cubs have died at Bannerghatta Biological Park in Bengaluru after being infected by a highly contagious virus, officials said on Tuesday. Feline panleukopenia (FP) is a viral disease of cats caused by the feline parvovirus. Kittens are most severely affected by the virus, they said. The seven cubs were aged between three and eight months. All of them were vaccinated but succumbed during the course of treatment. According to officials, the first outbreak was reported on August 22. Executive Director of Bannerghatta Biological Park, AV Surya Sen said though the seven cubs were vaccinated, they were still infected. “It is now under control and in the last 15 days, no deaths have been reported. We have completely broken the chain and taken all necessary measures. We followed all the required procedure and also held discussions with all our senior veterinarians. All correct course of action was taken. Also, we have ensured hygiene of the entire zoo and the rescue centre wa...

Power supply, healthcare facilities remain concern for Asia’s oldest monastery

Uninterrupted power supply and access to medical care remain important worries for Asia’s oldest monastery in Arunachal Pradesh’s Tawang. The waste left behind by the monastery’s expanding number of tourists has also become a source of concern for Abbot Shedling Tulku Thupten Tendar Rinpoche, the monastery’s chief. The Rinpoche, who has been the head of the Tawang Monastery for a year, is pleased with the monks and learners under him, but he is concerned about other facilities accessible to them. Tawang Monastery is Asia’s second largest and oldest. It was established between 1680 and 1681. Speaking to PTI in his native Tibetan through an interpreter, Rinpoche said, “The monks of our monastery are much disciplined and concentrate on their studies. They have been following the laid-down traditions well enough. “For us, one major issue is healthcare facilities. In case of any health-related emergency, our monks have to travel to Guwahati or Tezpur. If the government can ensure simil...